摘要
BACKGROUND: Lung adenocarcinoma (LUAD) is a common pulmonary malignant disease with a poor prognosis. There were limited studies investigating the influences of the tumor immune microenvironment on LUAD patients' survival and response to immune checkpoint inhibitors (ICIs). METHODS: Based on TCGA-LUAD dataset, we constructed a prognostic immune signature and validated its predictive capability in the internal as well as total datasets. Then, we explored the differences of tumor-infiltrating lymphocytes, tumor mutation burden, and patients' response to ICI treatment between the high-risk score group and low-risk score group. RESULTS: This immune signature consisted of 17 immune-related genes, which was an independent prognostic factor for LUAD patients. In the low-risk score group, patients had better overall survival. Although the differences were non-significant, patients with low-risk scores had more tumor-infiltrating follicular helper T cells and fewer macrophages (M0), which were closely related to clinical outcomes. Additionally, the total TMB was markedly decreased in the low-risk score group. Using immunophenoscore as a surrogate of ICI response, we found that patients with low-risk scores had significantly higher immunophenoscore. CONCLUSION: The 17-immune-related genes signature may have prognostic and predictive relevance with ICI therapy but needs prospective validation.
学科与关键词
- CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaZhang, Minghui; Ma, Jianli; Guo, Qiuyue; Ding, Shuang; Wang, Yan; Pu, Haihong*Frontiers in Immunology, 2022, 13: 806877.被引 12
- Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinomaCao, Kui; Liu, Mingdong; Ma, Keru; Jiang, Xiangyu; Ma, Jianqun*; Zhu, Jinhong*Cancer Immunology, Immunotherapy, 2022, 71(6): 1295-1311.被引 14
- A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatmentsWang, Chenghao; Lu, Tong; Xu, Ran; Chang, Xiaoyan; Luo, Shan; Peng, Bo; Wang, Jun; Yao, Lingqi; Wang, Kaiyu; Shen, Zhiping; Zhao, Jiaying*; Zhang, Linyou*Journal of Thoracic Disease, 2022, 14(6): 2131-+.被引 2
